Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

FDA approves Phase 3 trial for coronavirus drug

By Sean Whooley | May 20, 2020

Octapharma announced today that the FDA approved its investigational new drug (IND) application for a Phase 3 clinical trial for its drug therapy in COVID-19 patients.

Octagam 10% [Immune Globulin Intravenous (Human)] therapy will be observed for efficacy and safety in use with COVID-19 patients with severe disease progression, according to a news release.

The primary objective of the randomized, double-blind, placebo-controlled, multicenter study is to determine if high-dose Octagam 10% therapy will slow or stop respiratory deterioration in patients with severe disease progression. The study’s secondary objective is to measure the effects of Octagam 10% in relation to slowing or stopping the clinical progression of the virus by improving pulmonary function, quality of life and correlated impact on metabolic factors.

“Although many therapies based on provisional data have been proposed for patients who suffer from COVID-19, known treatments are limited,” Octapharma USA president Flemming Nielsen said in the release. “Intravenous immunoglobulin (IVIG), which consists of pooled IgG preparations from thousands of donors, has been used to treat patients with immune-mediated diseases for almost 40 years. Our hypothesis is that the use of IVIG in the prophylaxis of severe infections, especially in immunocompromised patients, makes it an attractive therapeutic possibility for COVID-19.”

Octapharma said it will begin the study immediately across 10 U.S. research sites with intentions to enroll about 54 adult patients diagnosed with COVID-19 with a resting SpO2 of ≤93%, requiring oxygen supplementation

Patients will be randomized to receive either Octagam 10% treatment or a placebo and will be monitored for approximately 33 days. The company hopes to report study results by the third quarter of 2020.

“Several case reports on utilizing IVIG treatment for COVID-19 patients have shown positive results,” Octapharma head of R&D Dr. Wolfgang Frenzel said. “The effects of the immune-modulating properties of IVIG in severely-ill COVID-19 patients appeared to be demonstrated in the case reports and we are, therefore, hopeful that we will observe improved clinical status in the patients receiving Octagam 10%.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pharma researcher charged with theft of trade secrets  
Norway investigating deaths of 23 individuals who received COVID-19 vaccine
Pharma image
Here’s what molecular shape can tell you about pharma innovation
Remdesivir
3 notable types of innovative drugs from 2020

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards